Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-25-027319
Filing Date
2025-04-02
Accepted
2025-04-01 17:49:18
Documents
59
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT ea0232165-10k_denalicap.htm   iXBRL 10-K 999336
2 INSIDER TRADING POLICY ea023216501ex19-1_denalicap.htm EX-19.1 66890
3 LIST OF SUBSIDIARIES ea023216501ex21-1_denalicap.htm EX-21.1 1865
4 CERTIFICATION ea023216501ex31-1_denalicap.htm EX-31.1 9195
5 CERTIFICATION ea023216501ex31-2_denalicap.htm EX-31.2 9761
6 CERTIFICATION ea023216501ex32-1_denalicap.htm EX-32.1 3392
7 CERTIFICATION ea023216501ex32-2_denalicap.htm EX-32.2 3560
  Complete submission text file 0001213900-25-027319.txt   5349480

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE deca-20241231.xsd EX-101.SCH 41076
9 XBRL CALCULATION FILE deca-20241231_cal.xml EX-101.CAL 19510
10 XBRL DEFINITION FILE deca-20241231_def.xml EX-101.DEF 243654
11 XBRL LABEL FILE deca-20241231_lab.xml EX-101.LAB 377979
12 XBRL PRESENTATION FILE deca-20241231_pre.xml EX-101.PRE 248813
61 EXTRACTED XBRL INSTANCE DOCUMENT ea0232165-10k_denalicap_htm.xml XML 474009
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41351 | Film No.: 25801193
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)